Mumps antibody response in young adults after a third dose of measles-mumps-rubella vaccine

Open Forum Infectious Diseases

Volumn 1, Issue 3, 2014, Pages

  Fiebelkorn, Amy Parker ^a   Coleman, Laura A ^b   Belongia, Edward A ^b   Freeman, Sandra K ^b   York, Daphne ^b   Bi, Daoling ^a   Zhang, Cheryl ^c   Ngo, Laurie ^c   Rubin, Steven ^c  

^a NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^b MARSHFIELD CLINIC   (United States)

^c CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

Author keywords

Immunization; Mumps; Mumps immunogenicity; Third dose measles mumps rubella (MMR) vaccine; Vaccinepreventable disease

Indexed keywords

MEASLES MUMPS RUBELLA VACCINE; NEUTRALIZING ANTIBODY;

ADULT; ANIMAL CELL; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; DISEASE PREDISPOSITION; FEMALE; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MUMPS; NONHUMAN; PRIORITY JOURNAL; YOUNG ADULT;

EID: 84978327770     PISSN: None     EISSN: 23288957     Source Type: Journal    
DOI: 10.1093/ofid/ofu094     Document Type: Article

References (39)

1. Rubin SA, Plotkin SA. Mumps vaccine. In: Plotkin SA, Orenstein WA, Offit PA, eds. Vaccines. 6th ed. Saunders, 2013:419-46.
2. Centers for Disease Control and Prevention. Mumps vaccine. MMWR Morb Mortal Wkly Rep 1977; 26:393-4.
3. Centers for Disease Control and Prevention. Measles prevention: supplementary statement. MMWR Morb Mortal Wkly Rep 1989; 38:11-4.
4. Barskey AE, Glasser JW, LeBaron CW. Mumps resurgences in the United States: a historical perspective on unexpected elements. Vaccine. 2009; 27:6186-95.
5. Department of Health and Human Services. Healthy People 2010: understanding and improving health. 2nd ed. Washington, DC: Government Printing Office, 2000.
6. Katz SL, Hinman AR. Summary and conclusions: measles elimination meeting, 16-17 March 2000. J Infect Dis 2004; 189(suppl 1):S43-7.
7. Reef SE, Cochi SL. The evidence for the elimination of rubella and congenital rubella syndrome in the United States: a public health achievement. Clin Infect Dis 2006; 43(suppl 3):S123-5.
8. US Department of Health and Human Services. Healthy People 2020. Washington, DC: Government Printing Office, 2010.
9. Dayan GH, Quinlisk MP, Parker AA, et al. Recent resurgence of mumps in the United States. N Engl J Med 2008; 358:1580-89.
10. Ogbuanu IU, Kutty PK, Hudson JM, et al. Impact of a third dose of measles-mumps-rubella vaccine on a mumps outbreak. Pediatrics. 2012; 130:e1567-74.
11. Nelson GE, Aguon A, Valencia E, et al. Epidemiology of a mumps outbreak in a highly vaccinated island population and use of a third dose of measles-mumps-rubella vaccine for outbreak control-Guam 2009-2010 Pediatr Infect Dis J 2013; 4:374-80.
12. Centers for Disease Control and Prevention. Mumps outbreak on a university campus-California, 2011. MMWR Morb Mortal Wkly Rep 2012; 61:986-9.
13. Levine H, Rishpon S, Huerta-Hartal M, et al. Preventing mumps outbreaks in confined settings: comprehensive ring vaccination as a containment strategy. Hum Vaccin. 2011; 7:1389-93.
14. Whelan J, van Binnendijk R, Greenland K, et al. Ongoing mumps outbreak in a student population with high vaccination coverage, Netherlands, 2010 Euro Surveill 2010; 15.
15. Bangor-Jones RD, Dowse GK, Giele CM, et al. A prolonged mumps outbreak among highly vaccinated Aboriginal people in the Kimberley region of Western Australia. Med J Aust 2009; 191:398-401.
16. Roberts C, Porter-Jones G, Crocker J, et al. Mumps outbreak on the island of Anglesey, North Wales, December 2008-January 2009. Euro Surveill 2009; 14.
17. McLean HQ, Fiebelkorn AP, Temte JL, et al.; Centers for Disease Control and Prevention. Prevention of measles, rubella, congenital rubella syndrome, and mumps, 2013: summary recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2013; 62:1-34.
18. Advisory Committee on Immunization Practices, Centers for Disease Control and Prevention. Immunization of health-care personnel: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2011; 60:1-45.
19. Military Vaccine Agency. Mumps infection and mumps vaccine: information paper. http://www.vaccines.mil/documents/1485MIP-Mumps. pdf. Accessed 29 August 2013.
20. The American College of Obstetricians and Gynecologists. Routine tests in pregnancy: frequently asked questions. http://www.acog.org/~/media/for%20patients/faq133.pdf?dmc=1&ts=20130228t1231184484 Accessed 29 August 2013.
21. Date AA, Kyaw MH, Rue AM, et al. Long-term persistence of mumps antibody after receipt of 2 measles-mumps-rubella (MMR) vaccinations and antibody response after a third MMR vaccination among a university population. J Infect Dis 2008; 197:1662-8.
22. Latner DR, McGrew M, Williams NJ, et al. Estimates of mumps seroprevalence may be influenced by antibody specificity and serologic method. Clin Vaccine Immunol 2014; 21:286-97.
23. LeBaron CW, Forghani B, Beck C, et al. Persistence of mumps antibodies after 2 doses of measles-mumps-rubella vaccine. J Infect Dis 2009; 199:552-60.
24. LeBaron CW, Bi D, Sullivan BJ, et al. Evaluation of potentially common adverse events associated with the first and second doses of measlesmumps-rubella vaccine. Pediatrics 2006; 118:1422-30.
25. LeBaron CW, Beeler J, Sullivan BJ, et al. Persistence of measles antibodies after 2 doses of measles vaccine in a postelimination environment. Arch Pediatr Adolesc Med 2007; 161:294-301.
26. LeBaron CW, Forghani B, Matter L, et al. Persistence of rubella antibodies after 2 doses of measles-mumps-rubella vaccine. J Infect Dis 2009; 200:888-99.
27. Watson JC, Hadler SC, Dykewicz CA, et al. Measles, mumps, and rubella-vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1998; 47:1-57.
28. Albrecht P, Herrmann K, Burns GR. Role of virus strain in conventional and enhanced measles plaque neutralization test. J Virol Methods. 1981; 3:251-60.
29. Ennis FA. Immunity to mumps in an institutional epidemic. Correlation of insusceptibility to mumps with serum plaque neutralizing and hemagglutination-inhibiting antibodies. J Infect Dis 1969; 119:654-7.
30. Kärber G. Beitrag zur kollektiven Behandlung pharmakologischer Reihenversuche. Arch Exp Path Pharmak 1931; 162:480-7.
31. Cortese MM, Barskey AE, Tegtmeier GE, et al. Mumps antibody levels among students before a mumps outbreak: in search of a correlate of immunity. J Infect Dis 2011; 204:1413-22.
32. Hersh BS, Fine PE, Kent WK, et al. Mumps outbreak in a highly vaccinated population. J Pediatr 1991; 119:187-93.
33. Galazka AM, Robertson SE, Kraigher A. Mumps and mumps vaccine: a global review. Bull World Health Organ 1999; 77:3-14.
34. Deeks SL, Lim GH, Simpson MA, et al. An assessment of mumps vaccine effectiveness by dose during an outbreak in Canada. CMAJ 2011; 183:1014-20.
35. Schaffzin JK, Pollock L, Schulte C, et al. Effectiveness of previous mumps vaccination during a summer camp outbreak. Pediatrics 2007; 120:e862-8.
36. Cheek JE, Baron R, Atlas H, et al. Mumps outbreak in a highly vaccinated school population. Evidence for large-scale vaccination failure. Arch Pediatr Adolesc Med 1995; 149:774-8.
37. Cohen C, White JM, Savage EJ, et al. Vaccine effectiveness estimates, 2004-2005 mumps outbreak, England. Emerg Infect Dis 2007; 13:12-7.
38. Wharton M, Cochi SL, Hutcheson RH, et al. A large outbreak of mumps in the postvaccine era. J Infect Dis 1988; 158:1253-60.
39. Rubin SA, Qi L, Audet SA, et al. Antibody induced by immunization with the Jeryl Lynn mumps vaccine strain effectively neutralizes a heterologous wild-type mumps virus associated with a large outbreak. J Infect Dis 2008; 198:508-15.